ND · State regulatory reference
North Dakota.
Moderate
North Dakota takes a conventional, USP-aligned posture with no peptide/GLP-1-specific rule and no documented board enforcement. Telemedicine practice of medicine and prescribing are governed by N.D. Cent. Code § 43-17-44, which requires a licensee to establish a bona fide relationship with the patient before diagnosis or treatment, held to the same standard of care as in-person. Compounding under NDAC 61-02-01-03 (Board of Pharmacy) adopts USP <795> (nonsterile) and <797> (sterile), plus <800> for hazardous drugs, with no state-specific additions or GLP-1/semaglutide restriction beyond federal 503A.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
N.D. Cent. Code § 43-17-44 permits an initial exam to be performed entirely via telemedicine if 'equivalent to an in-person examination,' but a bona fide patient-licensee relationship must be established first; a static online questionnaire or audio-only conversation alone does not meet the standard of care, so synchronous audio-video (or equivalent) is effectively required to prescribe.
Compounding
NDAC 61-02-01-03 adopts USP <795> (nonsterile), <797> (sterile), and <800> (hazardous); it contains no GLP-1/semaglutide-specific limitation or state addition beyond standard 503A practice.
Sources